BioSpace News Archive

Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today provided an important update on the continuing progress of the Phase 4 post-marketing confirmatory study of ADUHELM ® (aducanumab-avwa) 100 mg/mL injection for intravenous use in Alzheimer’s disease.

Inceptor Bio today announced that it has executed an in-licensing agreement with the University of California, Santa Barbara (UCSB) for an investigational Chimeric Antigen Receptor Macrophage (CAR-M) therapy targeting difficult-to-treat tumors.

Evofem Biosciences, Inc. (NASDAQ: EVFM) and Orion Biotechnology Canada Ltd. today announced that they have entered into a collaboration agreement to evaluate the compatibility and stability of Orion’s novel CCR5 antagonist, OB-002.

Robert Mabry, Ph.D. joins as Chief Scientific Officer from Takeda Pharmaceuticals and Nishla Keiser, Ph.D., J.D. appointed as Chief Legal and Strategy Officer from Intellia Therapeutics.

Be Bio Announces Appointment of Jay Backstrom, M.D., M.P.H., to Board of Directors.

Forma Therapeutics Holdings, Inc. today announced the company’s investigational oral, selective mIDH1 inhibitor combined with azacitidine yielded durable complete remission (CR) or CR with partial hematologic recovery (CRh) responses with favorable tolerability in patients with the mIDH1 form of acute myeloid leukemia (AML).

Paragon 28, Inc. announced today that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO, will virtually present at the 24th Annual Needham Growth Conference on Monday, January 10th .

The life science group Sartorius is expanding its bioanalytics portfolio by acquiring a majority stake in ALS Automated Lab Solutions GmbH.

Cerba HealthCare, a leading global player in medical diagnosis, today announced it has reached agreement to acquire Viroclinics-DDL, a fast-growing global virology and immunology contract research organization (CRO) from Summit Partners.

Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in GPCR-focused structure-based drug design (SBDD) and development, and Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced a strategic collaboration to discover therapeutic antibodies against G protein-coupled receptors (GPCR) identified by Sosei Heptares.